{"nctId":"NCT00412360","briefTitle":"Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)","startDateStruct":{"date":"2006-12"},"conditions":["Acute Myelogenous Leukemia","Acute Lymphocytic Leukemia","Chronic Myelogenous Leukemia","Myelodysplastic Syndrome","Natural Killer Cell Lymphoblastic Leukemia/Lymphoma"],"count":224,"armGroups":[{"label":"Single Cord Blood Transplant","type":"EXPERIMENTAL","interventionNames":["Biological: Single Umbilical Cord Blood Unit Transplant","Radiation: Total Body Irradiation","Drug: Cyclophosphamide","Drug: Fludarabine","Drug: Cyclosporine A","Drug: Mycophenolate Mofetil"]},{"label":"Double Cord Blood Transplant","type":"EXPERIMENTAL","interventionNames":["Biological: Double Umbilical Cord Blood Unit Transplant","Radiation: Total Body Irradiation","Drug: Cyclophosphamide","Drug: Fludarabine","Drug: Cyclosporine A","Drug: Mycophenolate Mofetil"]}],"interventions":[{"name":"Single Umbilical Cord Blood Unit Transplant","otherNames":[]},{"name":"Double Umbilical Cord Blood Unit Transplant","otherNames":[]},{"name":"Total Body Irradiation","otherNames":["TBI"]},{"name":"Cyclophosphamide","otherNames":["Cytoxan®"]},{"name":"Fludarabine","otherNames":["Fludara"]},{"name":"Cyclosporine A","otherNames":["CSA"]},{"name":"Mycophenolate Mofetil","otherNames":["MMF, Cellcept®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Two partially HLA-matched UCB units. Units must be HLA-matched minimally at 4 of 6 HLA-A and B (at intermediate resolution by molecular typing) and DRB1 (at high resolution by molecular typing) loci with the patient, and the units must be HLA-matched at 3 of 6 HLA- A, B, DRB1 loci with each other (using same resolution of molecular typing as indicated above). Two appropriately HLA-matched units must be available such that one unit delivers a pre-cryopreserved nucleated cell dose of at least 2.5 x 10\\^7 per kilogram and the second unit at least 1.5 x 10\\^7 per kilogram.\n* Acute myelogenous leukemia (AML) at the following stages:\n\n  1. High risk first complete remission (CR1), defined as the following:\n\n     * Having preceding myelodysplasia (MDS)\n     * High risk cytogenetics (high risk cytogenetics: del (5q) -5, -7, abn (3q), t (6;9) complex karyotype \\[at least 5 abnormalities\\],)the presence of a high FLT3 ITD-AR (\\> 0.4)\n     * Requiring more than 1 cycle of chemotherapy to obtain complete remission (CR);\n     * FAB M6\n  2. Second or greater CR\n  3. First relapse with less than 25% blasts in bone marrow\n  4. Morphologic complete remission with incomplete blood count recovery\n* Therapy-related AML for which prior malignancy has been in remission for at least 12 months\n* Acute lymphocytic leukemia (ALL) at the following stages:\n\n  1. High risk first remission, defined as one of the following conditions:\n\n     * Philadelphia chromosome-positive adult lymphoblastic leukemia (Ph+ ALL)\n     * Mixed lineage leukemia (MLL) rearrangement with slow early response (defined as having M2 \\[5-25% blasts\\] or M3 \\[more than 25% blasts on bone marrow examination on Day 14 of induction therapy\\])\n     * Hypodiploidy (less than 44 chromosomes or DNA index less than 0.81)\n     * End of induction M3 bone marrow\n     * End of induction M2 with M2-3 at Day 42\n     * Evidence of minimal residual disease (MRD). If a patient's only high risk criterion is MRD, approval by a protocol chair or protocol officer is required for enrollment. For COG centers, this will only be for MRD greater than 1 percent by flow MRD at the end of extended induction.\n  2. High risk second remission, defined as one of the following conditions:\n\n     * Philadelphia chromosome-positive adult lymphoblastic leukemia (Ph+ ALL)\n     * Bone marrow relapse less than 36 months from induction\n     * T-lineage relapse at any time\n     * Very early isolated central nervous system (CNS) relapse (6 months from diagnosis)\n     * Slow reinduction (M2-3 at Day 28) after relapse at any time\n     * Evidence of minimal residual disease (MRD). If a patient's only high risk criterion is MRD, approval by a protocol chair or protocol officer is required for enrollment. For COG centers, this will only be for MRD greater than 1 percent by flow MRD at the end of extended induction.\n  3. Any third or subsequent CR\n* NK cell lymphoblastic leukemia in any CR\n* Biphenotypic or undifferentiated leukemia in any CR or if in first relapse must have less than 25% blasts in bone marrow (BM)\n* Myelodysplastic syndrome (MDS) at any stage\n* Chronic myelogenous leukemia (CML) in chronic or accelerated phase\n* All patients with evidence of CNS leukemia must be treated and be in CNS CR to be eligible for study.\n* Patients 16 years old or older must have a Karnofsky score of at least 70% and patients younger than 16 years old must have a Lansky score of at least 70%.\n* Patients with adequate physical function as measured by:\n\n  1. Cardiac: Left ventricular ejection fraction greater than 40% or shortening fraction greater than 26%\n  2. Hepatic: Bilirubin no more than 2.5 mg/dL; alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) no more than 5 times the upper limit of normal (ULN)\n  3. Renal: Serum creatinine within normal range for age, or if serum creatinine is outside normal range for age, then renal function (creatinine clearance or GFR) greater than 70 mL/min/1.73 m\\^2\n  4. Pulmonary: Diffusing capacity of the lung for carbon monoxide (DLCO), forced expiratory volume in one second (FEV1), or forced vital capacity (FVC) greater than 50% of predicted value (corrected for hemoglobin); if unable to perform pulmonary function tests, then O2 saturation greater than 92% of room air\n\nExclusion Criteria:\n\n* Pregnant (β-positive human chorionic gonadotropin \\[HCG\\]) or breastfeeding\n* Evidence of HIV infection or HIV positive serology\n* Current uncontrolled bacterial, viral, or fungal infection (currently taking medication and progression of clinical symptoms)\n* Autologous transplant less than 12 months prior to enrollment\n* Prior autologous transplant for the disease for which the UCB transplant will be performed\n* Prior allogeneic hematopoietic stem cell transplant\n* Active malignancy other than the one for which the UCB transplant is being performed within 12 months of enrollment\n* Inability to receive TBI\n* Requirement of supplemental oxygen\n* HLA-matched related donor able to donate","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","maximumAge":"21 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Overall Survival","description":"Overall survival is defined as survival of death from any cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Disease-free Survival","description":"Disease-free survival is defined as survival without relapse of the primary disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Neutrophil and Platelet Engraftment","description":"Neutrophil engraftment is defined as achieving an absolute neutrophil count greater than 500x10\\^6/liter for three consecutive measurements on different days. The first of the three days will be designated the day of neutrophil engraftment. Platelet engraftment is defined as achieving platelet counts greater than 50,000/microliter for consecutive measurements over 7 days without requiring platelet transfusions. The first of the 7 days will be designated the day of platelet engraftment. Subjects must not have had platelet transfusions during the preceding 7 days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Neutrophil and Platelet Engraftment","description":"Platelet engraftment is defined as achieving platelet counts greater than 50,000/microliter for consecutive measurements over 7 days without requiring platelet transfusions. The first of the 7 days will be designated the day of platelet engraftment. Subjects must not have had platelet transfusions during the preceding 7 days.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"84","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Acute Graft-versus-host Disease (GVHD)","description":"Acute GVHD is graded according to the scoring system proposed by Przepiorka et al.1995:\n\nSkin stage:\n\n0: No rash\n\n1. Rash \\<25% of body surface area\n2. Rash on 25-50% of body surface area\n3. Rash on \\> 50% of body surface area\n4. Generalized erythroderma with bullous formation\n\nLiver stage (based on bilirubin level)\\*:\n\n0: \\<2 mg/dL\n\n1. 2-3 mg/dL\n2. 3.01-6 mg/dL\n3. 6.01-15.0 mg/dL\n4. \\>15 mg/dL\n\nGI stage\\*:\n\n0: No diarrhea or diarrhea \\<500 mL/day\n\n1. Diarrhea 500-999 mL/day or persistent nausea with histologic evidence of GVHD\n2. Diarrhea 1000-1499 mL/day\n3. Diarrhea \\>1500 mL/day\n4. Severe abdominal pain with or without ileus \\* If multiple etiologies are listed for liver or GI, the organ system is downstaged by 1.\n\nGVHD grade:\n\n0: All organ stages 0 or GVHD not listed as an etiology I: Skin stage 1-2 and liver and GI stage 0 II: Skin stage 3 or liver or GI stage 1 III: Liver stage 2-3 or GI stage 2-4 IV: Skin or liver stage 4","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Chronic GVHD","description":"Incidences of chronic GVHD will be graded per Shulman et al. 1980. This reference categorizes chronic GVHD as either limited or extensive. For this outcome, participants developing either type are considered to have a chronic GVHD event.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Infections Per Participant","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"9","spread":null}]},{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"13","spread":null}]},{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"15","spread":null}]},{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"10","spread":null}]},{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"15","spread":null}]},{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"12","spread":null}]},{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"24","spread":null}]},{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Relapse","description":"Relapse is defined by either morphological or cytogenetic evidence of AML, ALL, CML, or MDS consistent with pre-transplant features. Testing for recurrent malignancy in the blood, marrow or other sites will be used to assess relapse after transplantation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Treatment-related Mortality","description":"Treatment related mortality is defined as death without relapse of the primary disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Engraftment Syndrome","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":112},"commonTop":[]}}}